Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Hochhaus A, et al. Among authors: malek k. N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31. N Engl J Med. 2024. PMID: 38820078 Clinical Trial.
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U. Zeidan AM, et al. Among authors: malek k. Lancet Haematol. 2024 Jan;11(1):e38-e50. doi: 10.1016/S2352-3026(23)00333-2. Epub 2023 Dec 5. Lancet Haematol. 2024. PMID: 38065203 Clinical Trial.
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
Ng K, Tabernero J, Hwang J, Bajetta E, Sharma S, Del Prete SA, Arrowsmith ER, Ryan DP, Sedova M, Jin J, Malek K, Fuchs CS. Ng K, et al. Among authors: malek k. Clin Cancer Res. 2013 Jul 15;19(14):3987-95. doi: 10.1158/1078-0432.CCR-13-0027. Epub 2013 Jun 6. Clin Cancer Res. 2013. PMID: 23743569 Free PMC article. Clinical Trial.
Materials Acceleration Platforms (MAPs): Accelerating Materials Research and Development to Meet Urgent Societal Challenges.
Stier SP, Kreisbeck C, Ihssen H, Popp MA, Hauch J, Malek K, Reynaud M, Goumans TPM, Carlsson J, Todorov I, Gold L, Räder A, Wenzel W, Bandesha ST, Jacques P, Garcia-Moreno F, Arcelus O, Friederich P, Clark S, Maglione M, Laukkanen A, Castelli IE, Carrasco J, Cabanas MC, Stein HS, Ozcan O, Elbert D, Reuter K, Scheurer C, Demura M, Han SS, Vegge T, Nakamae S, Fabrizio M, Kozdras M. Stier SP, et al. Among authors: malek k. Adv Mater. 2024 Nov;36(45):e2407791. doi: 10.1002/adma.202407791. Epub 2024 Sep 6. Adv Mater. 2024. PMID: 39239995
169 results